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Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid 
organ transplantation (SOT). Most PTLD cases are associated with Epstein–Barr virus 
(EBV) infection. The role of antiviral prophylaxis or rituximab therapy for prevention 
of PTLD in SOT recipients is controversial. In a nationwide cohort, we assessed the in-
cidence, presentation, and outcome of histologically proven PTLD. We included 4765 
patients with a follow-up duration of 23 807 person-years (py). Fifty-seven PTLD 
cases were identified; 39 (68%) were EBV positive (EBV+ PTLD). Incidence rates for 
EBV+ PTLD at 1, 2, and 3 years posttransplant were 3.51, 2.24, and 1.75/1000 py and 
0.44, 0.25, and 0.29/1000 py for EBV− PTLD. We did not find an effect of antiviral 
prophylaxis on early and late EBV+ PTLD occurrence (early EBV+ PTLD: SHR 0.535 
[95% CI 0.199–1.436], p = .264; late EBV+ PTLD: SHR 2.213, [95% CI 0.751–6.521], 
p = .150). However, none of the patients (0/191) who received a rituximab-containing 
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1  |  INTRODUC TION
Posttransplant lymphoproliferative disease (PTLD) is one of the 
most serious complications of solid organ transplantation (SOT). 
Epstein–Barr virus (EBV) is known to play a major role in the devel-
opment of PTLD. However, EBV-negative PTLD accounts for 20%–
30% of cases.1 PTLD incidence ranges from 1% to 20% dependent 
on age,2 allograft type,3-5 type of induction treatment,3,6 inten-
sity of immunosuppressive therapy,3 time from transplant (early 
<1 year, late >1 year),7 and EBV serostatus of organ donor and 
recipient.8,9 Several PTLD prevention strategies for EBV high-risk 
SOT recipients (donor EBV positive, recipient EBV negative; D+/
R−), such as EBV DNAemia surveillance with reduction of immuno-
suppression when DNAemia increases or administration of the cy-
tolytic chimeric α-CD20 monoclonal antibody rituximab10-12 have 
been proposed. Even though high EBV DNAemia is a risk factor for 
the onset of PTLD,13,14 the time points for monitoring, source sam-
ples, and cutoff values for intervention are not standardized.7,15
Antiviral prophylaxis by (val-)acyclovir or (val-)ganciclovir to pre-
vent cytomegalovirus (CMV),16 herpes simplex virus (HSV), and vari-
cella-zoster virus (VZV) infection17,18 has an inhibitory effect on lytic 
EBV replication and viral shedding.19 Nevertheless, the role of anti-
viral prophylaxis in prevention of EBV-associated PTLD is controver-
sial. A previous, retrospective study reported a reduced incidence 
of PTLD (3.9% vs. 0.5%) after introduction of antiviral prophylaxis20 
and several other retrospective studies have supported its use.21,22 
These results have been challenged by more recent studies, which 
did not find a significant effect of antiviral prophylaxis on PTLD inci-
dence.23,24 In addition, a recent meta-analysis reported no reduction 
in the rate of EBV-associated PTLD in SOT recipients receiving anti-
viral prophylaxis by (val-)acyclovir or (val-)ganciclovir.25
In the hematologic stem cell transplant (HSCT) setting, the use 
of rituximab to prevent PTLD has become an initial preemptive in-
tervention in the context of EBV replication.26 Moreover, rituximab 
used as prophylaxis pretransplant was associated with a reduction in 
EBV replication and EBV+ PTLD in high-risk HSCT recipients.27 Less 
is known about the effect of rituximab on EBV+ PTLD occurrence in 
SOT recipients with EBV replication. Single center experiences have 
reported a reduction in PTLD rates with rituximab use in transplant 
recipients failing to respond to reducing immunosuppression com-
pared with historical or contemporaneous controls.12,28 To the best 
of our knowledge, the effect of rituximab, given as part of the induc-
tion regimen, on PTLD occurrence has not been studied yet.
The aim of this nationwide cohort study was to comprehensively 
describe the clinical characteristics of PTLD cases after SOT and to 
assess the effect of rituximab therapy and the use of antiviral pro-
phylaxis on PTLD occurrence.
2  |  MATERIAL S AND METHODS
2.1  |  Study design
We conducted a nested project based on data from the multicenter 
nationwide observational Swiss Transplant Cohort Study (STCS).29 
In the current study, we included all SOT recipients enrolled in the 
STCS from May 2008 to June 2019. Only the first transplantation 
was analyzed. All six Swiss transplant centers participate in the STCS, 
and for the analyzed period, around 95% of all recipients of SOT per-
formed in Switzerland consented to be included. The STCS and the 
current subproject were approved by the local ethics committee of 
each participating center (Ethics Commission of the Canton of Bern, 
Bern, Switzerland, Nr. 2019–00858).
2.2  |  Data collection
Clinical data on demographic characteristics, type of transplant, 
immunosuppressive regimen (induction and maintenance drugs, 
including rituximab), number of rejection episodes and rejection 
treatment (including rituximab), pretransplant donor and recipient 
CMV and EBV serostatus, administration and duration of antivi-
ral prophylaxis (ganciclovir, valganciclovir, acyclovir, valacyclovir), 
occurrence of HSV, VZV, or CMV infection (number of episode 
per patient, use of antiviral therapy), and the occurrence of PTLD 
were prospectively collected and extracted from the STCS data-
base. Additional data on PTLD (including localization, histopatho-
logical classification, and management) not captured in the STCS 
induction treatment experienced PTLD, but 57 of 4574 patients without rituximab 
induction developed PTLD. In an adjusted restricted mean survival time model, PTLD-
free survival was significantly longer (0.104 years [95% CI 0.077–0.131]) in patients 
receiving rituximab as induction treatment. This study provides novel data on the as-
sociation of rituximab induction and reduced risk for PTLD.
K E Y W O R D S
clinical research/practice, complication: infectious, hematology/oncology, immunosuppressant 
–fusion proteins and monoclonal antibodies: B cell specific, infection and infectious agents 
– viral, infection and infectious agents – viral: Epstein-Barr Virus (EBV), infectious disease, 
posttransplant lymphoproliferative disorder (PTLD)
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database were retrieved through a standardized data collection 
sheet from electronic medical records. Patient outcome (graft 
loss, death, death related to PTLD) were available from the STCS 
database. Treating physicians report systematically the most likely 
causes of death to the STCS using standardized data collection 
forms.
2.3  |  Clinical definitions
Histological confirmation was required for PTLD diagnosis. PTLD 
classification was based on World Health Organization criteria.30 
EBV-positive PTLD was identified by EBV-encoded RNA (EBER) in 
situ hybridization or latent membrane protein 1 (LMP1) histochemical 
stains. PTLD localization was categorized as nodal and extra-nodal 
or both. Early PTLD occurred in the first year after transplantation, 
late PTLD thereafter.
Viral infections are defined according to standard definitions 
generated by the Infectious Diseases Study Group of the STCS, 
as previously described.31 Each infection episode was validated 
by a Transplant Infectious Diseases specialist at each center. 
Furthermore, CMV infection and disease were classified according 
the definitions published by the American Society of Transplantation 
guidelines.32 We categorized SOT recipients to have rituximab-con-
taining induction regiments if rituximab was part of the induction 
treatment irrespective of the co-administration of additional agents. 
Antiviral prophylaxis was initiated at the discretion of the treating 
physician in accordance with local protocols. For this study, antiviral 
prophylaxis was defined as the use of (val-)ganciclovir or (val-)acy-
clovir started within the first 2 weeks after transplantation.18 Acute 
rejection was defined for each organ following the standard interna-
tional criteria.33
2.4  |  Statistical analyses
A descriptive analysis was performed to determine patients’ base-
line characteristics, transplant outcome variables (acute rejection, 
graft loss, death), and episodes of CMV, HSV, and VZV (median 
number of episodes per patient). Cumulative PTLD incidence was 
calculated overall and by organ group. The impact of antiviral proph-
ylaxis on EBV+ PTLD was analyzed using competing risk regression 
models (with death and graft loss as competing risk factors for EBV+ 
PTLD), adjusting for predefined confounding factors such as type 
of organ,3 EBV serostatus at transplantation,8 type of induction 
therapy,3 sex, and age.34 This was done separately for early and late 
EBV+ PTLD, since universal prophylaxis is given directly after trans-
plantation and the treatment effect might be different for the two 
time periods.15 The impact of rituximab induction therapy on PTLD 
incidence was analyzed using restricted mean survival time analysis 
(RMST) adjusting for sex, age, transplanted organ, antithymocyte 
globulin (ATG) use, and EBV serostatus at transplantation. Since no 
development of PTLD occurred in patients with rituximab induction, 
competing-risk regression models could not be used (violation of the 
proportional hazard assumption) for this analysis. RMST is a well-
established measure (based on differences in areas under Kaplan–
Meier curves of two groups) that can be interpreted as the average 
event-free survival time up to a prespecified time point.35 RMST is 
not dependent on the proportional hazards assumption.36 For this 
analysis, patients were censored at a maximum follow-up duration 
of 9 years, death, graft loss or lost to follow-up. The statistical analy-
sis was conducted using STATA version 15.
3  |  RESULTS
3.1  |  Study population
A total of 4765 SOT recipients (57% kidney, 22% liver, 9% lung, 8% 
heart, 5% combined) were included. Median age at transplanta-
tion was 54 years (interquartile range [IQR] 42–62 years), and 36% 
(1711/4765) of patients were female. Median follow-up time was 
4.61 years (IQR 2.22–7.62). EBV high-risk serostatus (D+/R−) was 
present in 6% (266/4765) of SOT recipients. Patient characteristics 
are detailed in Table 1.
3.2  |  Characteristics, treatment, and 
outcome of PTLD
Among 57 PTLD cases identified, 68% (39/57) were EBV+. Clinical 
characteristics, treatment, and outcome of PTLD cases are shown 
in Table 2.
The overall PTLD incidence was 2.39 per 1000 person-years (py) 
and the highest incidence was found among lung transplant recipi-
ents (5.77/1000 py; Table 2). The incidence of EBV+ PTLD was high-
est in the first-year posttransplant (3.51/1000 py), this was not the 
case for EBV− PTLD cases (Figure 1).
Histopathological classification revealed early lesions in 11% 
(6/57), polymorphic in 23% (13/57), and monomorphic PTLD in 67% 
(38/57) of cases. Most PTLDs were of B cell origin (95%; 54/57). 
Extra-nodal involvement was common (in 87% of EBV+ PTLD and 
78% of EBV− PTLD; Figure 2) and central nervous system (CNS) in-
volvement was exclusively found in EBV+ PTLD (21%; 8/39). PTLD 
lesions of the transplanted organ were detected in 29% (14/49) of 
patients with extra-nodal involvement and most of these lesions 
were EBV+ (79%; 11/14).
SOT recipients with EBV+ PTLD were younger compared to pa-
tients with EBV− PTLD (39 [IQR 20–59] vs. 61 years [IQR 54–63]; 
p < .01) and the median time from transplantation to PTLD diag-
nosis was shorter; 14.33 months (IQR 7.82–32.91) for EBV+ PTLD 
vs. 56.84 months (IQR 40.93–80.87; p < .001) for EBV− PTLD. EBV 
high-risk serostatus (D+/R−) was more frequent in EBV+ PTLD (33%; 
13/39) than in EBV− PTLD (0%; 0/18; p < .01).
Reducing immunosuppression alone was the treatment for 18% 
(7/39) of EBV+ PTLD cases while none of the EBV− PTLD cases were 
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TA B L E  1  Patient characteristics of recipients included in the analysis according to whether they developed PTLD, EBV associated or not
No PTLD PTLD EBV+ PTLD EBV− PTLD
Characteristics n = 4708 n = 57 n = 39 n = 18
Female, sex, n (%) 1689 (36) 22 (39) 19 (49) 3 (17)
Age at transplant, years, median (IQR) 54 (42–62) 47 (29–61) 39 (20–59) 61 (54–63)
Follow-up, years, median (IQR) 4.64 (2.22–7.64) 2.09 (0.75–4.04) 1.19 (0.65–2.74) 4.74 (3.41–6.74)
EBV serostatus, n (%)
EBV low-risk (D−/R−) 58 (1) 1 (2) 1 (3) 0 (0)
EBV intermediate-risk (R+) 4326 (92) 42 (74) 24 (62) 18 (100)
EBV high-risk (D+/R−) 253 (5) 13 (23) 13 (33) 0 (0)
Missing 71 (2) 1 (2) 1 (3) 0 (0)
CMV serostatus, n (%)
CMV low-risk (D−/R−) 925 (20) 15 (26) 12 (31) 3 (17)
CMV intermediate-risk (R+) 2827 (60) 31 (54) 20 (51) 11 (61)
CMV high-risk (D+/R−) 927 (20) 10 (18) 6 (15) 4 (22)
Missing 29 (1) 1 (2) 1 (3) 0 (0)
Transplant, n (%)
Kidney 2674 (57) 23 (40) 16 (41) 7 (39)
Liver 1018 (22) 16 (28) 8 (21) 8 (44)
Heart 358 (8) 4 (7) 3 (8) 1 (6)
Lung 431 (9) 11 (19) 10 (26) 1 (6)
Combined 227 (5) 3 (5) 2 (5) 1 (6)
Antiviral prophylaxis, n (%)
2097 (45) 30 (53) 25 (64) 5 (28)
(Val-)ganciclovir, n (%) 1872 (40) 23 (40) 18 (46) 5 (28)
(Val-)acyclovir, n (%) 225 (5) 7 (12) 7 (18) 0 (0)
Duration of acyclovir prophylaxis, days, 
median (IQR)
94.5 (84.0–179.0) 931.0 (8.0–1606.0) 931.0 (8.0–1606.0) 0
Duration of ganciclovir prophylaxis, days, 
median (IQR)
98.0 (79.0–173.0) 61.0 (10.0–125.0) 93.0 (10.0–170.0) 27.0 (15.0–61.0)
Any CMV infection, n (%) 1358 (29) 16 (28) 10 (26) 6 (33)
Any VZV infection, n (%) 158 (3) 2 (4) 0 (0) 2 (11)
Any HSV infection, n (%) 288 (6) 4 (7) 3 (8) 1 (6)
Induction regiment contained, n (%)
Basiliximab/Other 3075 (65) 41 (72) 28 (72) 13 (72)
ATG 1016 (22) 12 (21) 9 (23) 3 (17)
Rituximab 191 (4) 0 (0) 0 (0) 0 (0)
Unknown 426 (9) 4 (7) 2 (5) 2 (11)
Maintenance immunosuppression, n (%)
Glucocorticosteroids 4513 (97) 55 (96) 38 (97) 17 (94)
MMF 4054 (87) 48 (84) 32 (82) 16 (89)
Azathioprin 126 (3) 3 (5) 2 (5) 1 (6)
Cyclosporin 1047 (23) 17 (30) 14 (36) 3 (17)
Tacrolimus 3305 (71) 38 (67) 25 (64) 13 (72)
Everolimus 53 (1) 1 (2) 1 (3) 0 (0)
Sirolimus 23 (0) 0 (0) 0 (0) 0 (0)
Unknown 58 (1) 0 (0) 0 (0) 0 (0)
(Continues)
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managed by reducing immunosuppression alone. Rituximab mono-
therapy was given in 35% (20/57) of patients.
Forty-four percent (25/57) of patients diagnosed with PTLD 
died during follow-up, with most deaths attributed to PTLD (64%; 
16/25). PTLD-related mortality was similar among EBV+ PTLD 
and EBV− PTLD cases (33% vs. 26%; p = .55, overall 28%) and the 
median time to PTLD-related death did not differ among EBV+ 
PTLD (4.1 months [IQR 0.3–8.6]) and EBV− PTLD (7.3 months [IQR 
1.6–13.5]; p = .28).
3.3  |  EBV+ PTLD and antiviral prophylaxis
Overall, 44.6% (2127/4765) of patients received antiviral prophy-
laxis with (val-) ganciclovir (n = 1895) or with (val-)acyclovir (n = 232) 
for a median duration of 97 days (IQR 79–173). The rate of recipi-
ents receiving antiviral prophylaxis was dependent on the type of 
transplant. Antiviral prophylaxis was more frequently given to lung 
transplant recipients (94% [414/442]) compared to kidney (45%; 
1206/2697) heart (44%; 161/364), liver (22%; 230/1034), or com-
bined transplant recipients (50%; 116/230). SOT recipients receiving 
antiviral prophylaxis were younger (median age: 53 [IQR 39–61] vs. 
55 [IQR 43–62] years; p < .001) and more likely to have received 
ATG as part of the induction treatment (30% vs. 13%; p < .001) 
(Table S1). These patients also had a higher incidence of treatment 
requiring rejection episodes (221/1000 py [95% CI 209.4–233.9] vs. 
268.5/1000 py [95% CI 254.1–283.8]). The crude EBV+ PTLD inci-
dence rate in the first-year posttransplant was 3.87 of 1000 py (95% 
CI 1.94–7.73) for patients receiving antiviral prophylaxis versus 3.21 
of 1000 py (95% CI 1.61–6.41) for patients without antiviral prophy-
laxis (p = .35). A trend for a higher incidence rate was found for pa-
tients receiving (val-)acyclovir (8.89/1000 py [95% CI 2.22–35.58]) 
compared to (val-)ganciclovir (3.26/1000 py [95% CI 1.46–7.25]; 
p = .13) in the first-year after transplant.
Crude incidence of EBV+ PTLD for the entire follow-up duration 
was higher for patients receiving antiviral prophylaxis (2.31/1000 py 
[95% CI 0.64–1.82]) compared to patients not receiving prophylaxis 
(1.08/1000 py [95% CI 1.56–3.42]). In the adjusted risk regression 
model, we did not find an effect of antiviral prophylaxis on EBV+ 
PTLD incidence in the first-year posttransplant or beyond this pe-
riod (early EBV+ PTLD: SHR 0.535 [95% CI 0.199–1.436]; p = .264; 
late EBV+ PTLD: SHR 2.213 [95% CI 0.751–6.521]; Table 3). The re-
sults remained unchanged when comparing (val-)ganciclovir, which 
is believed to be more active against EBV than (val-) acyclovir,37 ver-
sus no antiviral prophylaxis (data not shown).
Variables significantly associated with a higher risk of EBV+ 
PTLD occurrence differed in early EBV+ PTLD (<1 year) compared to 
late (>1 year) EBV+ PTLD (Table 3).
3.4  |  PTLD and rituximab therapy
None of the 191 patients receiving rituximab as part of the induction 
treatment developed PTLD (Figure 3). Patients with rituximab induc-
tion therapy were younger (median age: 51 [IQR 41–61] vs. 54 [IQR 
42–62] years; p < .001). The EBV serostatus distribution among both 
groups was similar. Most SOT recipients receiving rituximab as in-
duction treatment were renal transplant recipients (95%; 182/191). 
The majority of these renal transplant recipients (88%; 161/182) re-
ceived rituximab as part of their induction therapy for AB0 incom-
patible renal transplantation (Table S2). In the adjusted restricted 
mean survival time model (RMST), the mean PTLD-free survival time 
at 9 years of follow-up was significantly shorter (0.104 years [95% CI 
0.077–0.131]) in patients not receiving rituximab as induction treat-
ment (competing-risk models were inappropriate due to violation 
of proportional hazard assumption; no PTLD occurred in patients 
receiving rituximab). Meaning that the average loss of PTLD-free 
survival time at 9 years was 0.104 years in the group not receiving 
rituximab (Figure S1). In addition, none of the recipients receiving 
rituximab for treatment of rejection (n = 121) experienced PTLD dur-
ing follow-up.
We performed a subanalysis restricted to renal transplant re-
cipients to analyze if the effect of rituximab on PTLD occurrence 
is also verifiable in this subgroup. This analysis (adjusted RMST) 
confirmed the findings seen in the overall cohort that, patients 
not receiving rituximab induction had a significant shorter mean 
PTLD-free survival time at 9 years follow-up (0.067 years [95% CI 
0.039–0.096]).
4  |  DISCUSSION
We assessed the clinical characteristics, incidence, and outcome 
of PTLD in a nationwide cohort (STCS). In addition, we explored 
the association of antiviral prophylaxis and rituximab induction 
therapy on PTLD occurrence. The major findings of our study are 
No PTLD PTLD EBV+ PTLD EBV− PTLD
Characteristics n = 4708 n = 57 n = 39 n = 18
Any rejection episode, n (%) 1794 (38) 21 (37) 13 (33) 8 (44)
Rejection episodes, n, median (IQR) 1 (1–3) 2 (1–2) 2 (1–2) 2 (2–2)
Treated rejection episodes, n, median (IQR) 1 (1–2) 1 (1–2) 1 (1–2) 2 (1–2)
Abbreviations: ATG, antithymocyte globulin; CMV, cytomegalovirus; D, donor; HSV, herpes simplex virus; IQR, interquartile range; MMF, 
mycophenolate mofetil; PTLD, posttransplant lymphoproliferative disorder; R, recipient; VZV, varicella-zoster virus.
Table 1 (Continued)
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as follows: (1) the PTLD incidence rate among Swiss SOT recipients 
was low and depended on the type of transplant; (2) extra-nodal 
involvement was common; (3) the mortality among SOT recipients 
with PTLD was high; (4) antiviral prophylaxis was not associated 
with a reduction of EBV+ PTLD occurrence; and (5) in contrast, 
rituximab induction therapy was associated with a reduced risk of 
PTLD occurrence.
The incidence rate of PTLD ranged from 1.59/1000 py to 
5.77/1000 py dependent on type of transplant which is lower than 
previously reported in other cohorts.24,38 This might be due to the 
effects of continuous improvement in prevention, such as screening 
for EBV DNAemia and preemptive reduction in immunosuppression, 
in the current era of transplant medicine.15 Incidence rates of EBV+ 
PTLD and EBV− PTLD differed over time. EBV+ PTLD incidence 
was highest in the first-year posttransplant (3.51/1000 py [95% CI 
2.14–5.72]) and decreased thereafter; this was not the case for EBV− 
PTLD (0.43/1000 py [95% CI 0.11–1.75]). The distinct temporal oc-
currence of EBV+ and EBV− PTLD potentially reflects the different 
biological entity of these two malignancies15,39,40 and may also ex-
plain the biphasic pattern of PTLD occurrence described in previous 
studies.41-43
In our study, most PTLDs had extra-nodal localization. Nodal in-
volvement was only found in about one third of cases. Interestingly, 
extra-nodal involvement of lymphomas in the general population 
TA B L E  2  PTLD incidence, classification, management, and outcome
Total EBV+ PTLD EVB− PTLD
n = 57 n = 39 n = 18
Overall PTLD incidence rate /1000 py (IQR)
according to organ transplant (IQR)
2.39 (1.84–3.11) 1.63 (1.19–2.24) 0.75 (0.47–1.2)
Kidney 1.59 (1.06–2.39) 1.01 (0.68–1.81) 0.48 (0.23–1.02)
Liver 3.41 (2.09–5.57) 1.71 (0.85–3.41) 1.71 (0.85–3.41)
Heart 2.41 (0.91–0.42) 1.81 (0.58–5.61) 0.60 (0.08–4.28)
Lung 5.77 (3.19–10.42) 5.24 (2.28–9.75) 0.52 (0.07–3.72)
Combined 2.68 (0.86–8.32) 1.79 (0.44–7.16) 0.89 (0.12–6.35)
PTLD WHO classification, n (%)
Early lesions 6 (11) 5 (13) 1 (6)
Polymorphic PTLD 13 (23) 12 (31) 1 (6)
Monomorphic PTLD 38 (67) 22 (56) 16 (89)
B cell PTLD, n (%) 54 (95) 38 (97) 16 (89)
T cell PTLD, n (%) 3 (5) 1 (3) 2 (11)
CD20 status, n (%)
Positive 43 (75) 31 (79) 12 (67)
Negative 7 (12) 5 (13) 2 (11)
Unknown 7 (12) 3 (8) 4 (22)
PTLD localization, n (%)
CNS 8 (14) 8 (21) 0 (0)
Extra-nodal 48 (84) 34 (87) 14 (78)
Nodal 8 (14) 4 (10) 4 (22)
Unknown 1 (2) 1 (3) 0 (0)
PTLD management, n (%)
Reduction of immunosuppression alone 7 (12) 7 (18) 0 (0)
Rituximab alone 20 (35) 14 (36) 6 (33)
Chemotherapy alone 5 (9) 1 (3) 4 (22)
Rituximab and chemotherapy 19 (33) 13 (33) 6 (33)
Other 6 (11) 4 (10) 2 (11)
PTLD outcome, n (%)
Died during follow-up 25 (44) 16 (41) 9 (50)
PTLD-related death 16 (28) 10 (26) 6 (33)
Time to PTLD-related death, month (IQR) 6.8 (1.3–12.9) 7.3 (1.6–13.5) 4.1 (0.3–8.6)
Abbreviations: CNS, central nervous system; IQR, interquartile range; PTLD, posttransplant lymphoproliferative disorder; py; person-years; WHO, 
World Health Organization.
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is less common44 and is associated with poor outcome.45 PTLD lo-
calization in the transplanted organ was mainly present in lung and 
liver recipients and more often found in EBV+ PTLD compared to 
EBV− PTLD (28% vs. 16%). Similar to our findings, previous stud-
ies also reported high rates of extra-nodal PTLD.46 In our cohort, 
PTLD-related mortality was around 30%. This is in line with findings 
of contemporary reports in pediatric47 and adult48 SOT PTLD pa-
tients. Present outcomes of patients, especially those with CD20+ 
PTLD, improved compared to historic reports, most likely as a re-
sult of the availability of rituximab and improved management of 
immunosuppression.15
Similar to previous reports, we identified different risk factors 
for early and late EBV+ PTLD.7 In our analysis, early EBV+ PTLD 
was associated with EBV high-risk (D+/R−) serostatus (SHR 18.586 
[95% CI 5.54–62.35]) and lung transplantation (SHR 5.98 [95% CI 
1.54–23.17]). We did not find an association between young age 
or induction therapy with ATG and the risk for early EBV+ PTLD as 
reported by others.38 Most likely, this is due to the underrepresen-
tation of pediatric patients in our cohort and the lower ATG doses 
used in the recent era compared to historical studies.15 Occurrence 
of late EBV+ PTLD was associated with young age at transplantation. 
However, this rather reflects an immortal person-time bias than a 
real finding.49 In cohorts with an exclusively adult population, higher 
age is associated with occurrence of late PTLD.7
When correcting for known risk factors, EBV+ PTLD incidence 
rates were similar with or without antiviral prophylaxis. This is in line 
with the findings of the most recent meta-analysis.25 There is a bio-
logically plausible explanation for our findings. EBV-active antiviral 
substances ((val-)ganciclovir, (val-)acyclovir)) are pro-drugs and need 
to undergo phosphorylation by a viral thymidine kinase (TK), but 
F I G U R E  1  EBV+ and EBV− PTLD incidence per 1000 person-years. Symbols represent point-estimates, whiskers 95% confidence 
intervals. EBV, Epstein–Barr virus; IR, incidence rate; PTLD, posttransplant lymphoproliferative disorder; py, person-years























  EBV- PTLD
IR/1000 py EBV+ PTLD 3.51 2.23 1.75 1.04 1.24 0.5 0.63
IR/1000 py EBV- PTLD 0.44 0.25 0.29 1.38 0.41 2.01 0.63
F I G U R E  2  Localization of PTLD according to EBV association. Each extra-nodal localization is counted separately (exceeds number of 
cases). CNS, central nervous system; EBV, Epstein–Barr virus; PTLD; posttransplant lymphoproliferative disorder
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EBV-transformed proliferating B cells are latently infected and do 
not express EBV TK proteins.50,51 Therefore, none of these antiviral 
agents can act on EBV-driven cell proliferation of B cells.
In our cohort, rituximab given as part of the induction regimen 
was associated with a reduced risk for PTLD. The difference in av-
erage loss of PTLD-free survival time at 9 years posttransplant 
(0.104 years [95% CI 0.077–0.131]) might appear small but the rarity 
of events and the large cohort have to be taken in to account when 
interpreting the data. The use of rituximab has become a common 
preemptive intervention strategy in EBV viremic HSCT recipients to 
reduce the risk of PTLD.26 Moreover, rituximab given prophylacti-
cally before or directly after HSCT was shown to reduce EBV rep-
lication52,53 and EBV+ PTLD in high-risk HSCT recipients.27 In SOT, 
reduced PTLD rates have been reported if rituximab was used pre-
emptively in heart12 and renal28 transplant recipients, who failed 
TA B L E  3  Risk factors of EBV+ PTLD early (<1 year) and late 




Early EBV+ PTLD (<1 year after transplant)
Sex
Female Reference
Male 1.030 (0.379–2.798) .953
Age 0.992 (0.967–1.017) .525
Antiviral prophylaxis
No prophylaxis Reference
Antiviral prophylaxis 0.535 (0.199–1.436) .264
EBV serostatus
Non high-risk (D−/R−)/(R+) Reference
High-risk (D+/R−) 18.586 (5.540–62.355) <.001
Induction therapy
No ATG Reference
ATG 1.284 (0.444–3.717) .645
Organ transplant
Kidney Reference
Liver 1.256 (0.269–5.851) .771
Heart 2.055 (0.476–8.881) .334
Lung 5.979 (1.542–23.176) .010
Combined 3.333 (0.470–23.604) .228
Late EBV+ PTLD (>1 year after transplant)
Sex
Female Reference
Male 0.0543 (0.229–1.283) .164
Age 0.965 (0.943–0.988) .003
Antiviral prophylaxis
No prophylaxis Reference
Antiviral prophylaxis 2.213 (0.751–6.521) .150
EBV serostatus
Non high-risk (D−/R−)/(R+) Reference
High-risk (D+/R−) 1.760 (0.605–5.120) .178
Induction therapy
No ATG Reference
ATG 1.847 (0.519–6.571) .343
Organ transplant
Kidney Reference
Liver 1.420 (0.502–4.015) .508
Heart 0.421 (0.045–3.927) .448
Lung 2.083 (0.650–6.669) .217
Combined 0.893 (0.094–8.497) .922
Abbreviations: ATG, antithymocyte globulin; EBV, Epstein–Barr 
virus; D, donor; IQR, interquartile range; PTLD, posttransplant 
lymphoproliferative disorder; R, recipient; SHR, subdistribution hazard 
ratio.
F I G U R E  3  (A,B) Probability of EBV+ PTLD (A) or PTLD (B) 
occurrence according to antiviral prophylaxis (A) or rituximab 
therapy (B). EBV, Epstein–Barr virus; PTLD; posttransplant 
lymphoproliferative disorder
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to control EBV DNAemia despite reduction in immunosuppression. 
Rituximab is already used in the context of desensitization before 
AB0-incompatible renal transplantation54 and has been given as sole 
induction therapy for renal transplantation.55 Side effects associated 
with rituximab mainly include an increased risk for infection56 and 
concerns about the emergence of CD20-negative PTLD after receiv-
ing rituximab were previously expressed.57 The potential effect of 
rituximab on subsequent PTLD occurrence might be attributable to 
the depletion of CD20+ B cells58 which represent the major reservoir 
for latent EBV infection. The reduced abundance of these cells at risk 
for malignant transformation might be linked to a lower risk for PTLD.
Our study has several limitations. The relatively small number of 
PTLD cases potentially affects the power to identify factors associ-
ated with increased or reduced risk for development of PTLD. We 
cannot exclude underreporting of PTLD in our cohort, in particular 
late posttransplant, when patients were not exclusively followed at 
the transplant center. However, SOT recipients are to be expected to 
be referred to a tertiary transplant center upon PTLD diagnosis and 
all referral centers participate in the STCS. The duration of antiviral 
prophylaxis was not available for a relevant proportion of SOT recip-
ients. In consequence, the effect of the duration of antiviral prophy-
laxis could not be adequately assessed. In addition, data on antiviral 
treatment duration for patients not receiving primary antiviral pro-
phylaxis were not available. The majority of SOT recipients receiving 
rituximab as induction therapy were renal transplant recipients (95%). 
Therefore, the association of rituximab therapy and a reduction of 
PTLD incidence might not apply for other SOT recipients. Our find-
ings regarding the effect of rituximab on PTLD occurrence are based 
on an observational study design, therefore we cannot exclude that 
this association is caused by confounding factors. However, we tried 
to address this by adjusting our multivariate model (restricted mean 
survival time model for rituximab use and development of PTLD) 
for confounding factors associated with PTLD including the type of 
transplanted organ, use of ATG, and EBV serostatus. To exclude that 
the effect of rituximab is solely caused by confounding due to a com-
parison of renal transplant patients with other transplant types which 
are associated with a higher PTLD risk, we performed a subgroup 
analysis restricted to renal transplant recipients. The association of 
a reduced PTLD incidence in patients with rituximab induction was 
also confirmed in this subgroup analysis. We therefore think that the 
reduced risk for PTLD development is rather associated with the use 
of rituximab and not by confounding factors.
In our study we did not address the potentially negative impact 
of rituximab induction. Therefore, we cannot provide an elaborated 
risk–benefit analysis of rituximab induction.
In summary, in this nationwide SOT cohort, PTLD incidence rate 
was low, but still associated with notable mortality. The incidence of 
EBV+ PTLD declined over time and was highest in the first-year post-
transplant, while EBV− PTLD incidence did not decline. There was no 
association between antiviral prophylaxis and PTLD incidence. We 
provide novel information that rituximab given as part of the induc-
tion regimen was associated with a decreased risk for PTLD occur-
rence. This finding needs to be confirmed in independent cohorts.
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